KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...
The Ukrainian 95th airborne assault brigade released drone footage on Monday said to show strikes on Russian troops in Kursk ...
help to make World Diabetes Day a global success by providing valuable support for the development of campaign resources and ...
which was curated using questions about medical conditions and their associated symptoms posted online. The researchers behind the project point to a number of possible applications, including ...
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
Hosted on MSN10h
'Polling Nostradamus' explains how he got his 2024 US Election prediction so badly wrong'Once you dissolve truth, democracy dissolves with it...we have never seen anything like this in the history of the country.' ...
Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback